Abstract:THESIS 11122%%%%The objective of this project was to explore clinical and molecular aspects of electroconvulsive therapy (ECT) in the treatment of depression, with a particular focus on the role of microRNAs (small, non-coding molecules that can regulate gene expression). The patients receiving ECT in this study were participants in a randomised controlled trial (the EFFECT-Dep Trial) of high-dose (6x seizure threshold) right unilateral and standard dose (1.5x seizure threshold) bitemporal brief-pulse ECT for depression. The objective of the EFFECT-Dep Trial was to compare the effectiveness and cognitive side-effects of these two forms of ECT. In this thesis, a systematic review and meta-analysis was carried out with a similar objective. PubMed, PsycInfo, Web of Science, Cochrane Library, Embase and the International Clinical Trials Registry Platform databases were searched for with the terms "electroconvulsive" or "electroshock" and "trial". Seven randomised controlled trials (n=792) met inclusion criteria, including the EFFECT-Dep Trial. Bitemporal ECT did not differ from high-dose unilateral ECT on depression rating change scores (Hedges?s g = -0.03; 95% confidence interval (CI) -0.17 to 0.11), remission (RR 1.06; 95% CI 0.93 to 1.20), or relapse at 12-months (RR 1.42; 95% CI 0.90 to 2.23). There was an advantage for unilateral ECT on reorientation time after individual ECT sessions (mean difference in minutes = -8.28; 95% CI -12.86 to -3.70) and retrograde autobiographical memory (Hedges?s g =-0.46, 95% CI=-0.87 to -0.04) after completing an ECT course. There were no differences for general cognition, category fluency and delayed visual and verbal memory. The immediate clinical implication of this is that high-dose right unilateral ECT should be considered as a first-line option when prescribing ECT. Peripheral blood samples from patients participating in the EFFECTDep Trial and healthy controls were collected in PaxGene? bottles. MicroRNAs and mRNAs were extracted using PaxGene? blood miRNA/RNA kits. An initial discovery phase deep sequencing study (n=16) was carried out on the SOLiD? platform. This yielded over 23 million reads mapping on to known microRNAs in the human genome. However, in the group as a whole there were no significant differences in microRNA levels from baseline to ECT following strict correction for multiple testing. However, post-hoc analysis indicated that there were significant changes in microRNA levels in patients with psychotic depression. These changes were confirmed in the same sample using quantitative real-time polymerase chain reaction (qRTPCR). In a separate cohort (37 depressed, 34 controls), candidate microRNAs from deep sequencing were analysed in a validation study. Two microRNAs (miR-126-3p and miR-106a-5p) were significantly elevated in patients with psychotic depression (n=7) at baseline when compared to healthy controls. After ECT treatment, the levels of these microRNAs normalised. Bioinformatic analysis revealed a high number of genes, molecular and biological processes…

Antidepressant electroconvulsive therapy: Mechanism of action, recent advances and limitations

How Electroconvulsive Therapy Works?: Understanding the Neurobiological Mechanisms

Effects of Electroconvulsive Therapy on Depression and Its Potential Mechanism

Electroconvulsive therapy: recent advances and anesthetic considerations

Electroconvulsive Therapy (ECT) in Major Depression: Oldies but Goodies

Potential Mechanisms Underlying the Therapeutic Effects of Electroconvulsive Therapy

The Neurobiological Effects of Electroconvulsive Therapy Studied Through Magnetic Resonance: What Have We Learned, and Where Do We Go?

Electroconvulsive Therapy Changes Immunological Markers in Patients With Major Depressive Disorder: A Scoping Review

Electroconvulsive Therapy Changes Immunological Markers in Patients With Major Depressive Disorder

Neuroimaging Biomarkers at Baseline Predict Electroconvulsive Therapy Overall Clinical Response in Depression: A Systematic Review

The influence of concomitant antidepressant and antipsychotic medication on antidepressant effect and seizure duration of electroconvulsive therapy

Neurobiological mechanisms of electroconvulsive therapy for depression: Insights into hippocampal volumetric increases from clinical and preclinical studies

Anesthetic Influence on Electroconvulsive Therapy: A Comprehensive Review

Electroconvulsive therapy regulates brain connectome dynamics in patients with major depressive disorder

Comparative efficacy and tolerability of different anesthetics in electroconvulsive therapy for major depressive disorder: A systematic review and network meta-analysis

Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A systematic review of animal models of depression

Amplitude-determined seizure-threshold, electric field modeling, and electroconvulsive therapy antidepressant and cognitive outcomes

Anesthesia Management for Electroconvulsive Therapy

Electroconvulsive therapy for depression : optimising treatment and exploring molecular mechanisms

Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy

Adjunctive psychotropic medications during electroconvulsive therapy in the treatment of depression, mania, and schizophrenia